Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform can address a wide range of autoimmune and immunologic diseases. Imotopes™ are modified synthetic peptides, which specifically block improper immune activity. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no effective therapeutic alternative and has the potential to cure patients without impairing their immune defenses.

Our vision is to become a leader in the field of active specific immunotherapy and to prevent, stop and potentially cure autoimmune diseases. 

Headquartered in Liège, Belgium, Imcyse was founded as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s Imotope™ technology platform is protected by a robust, international intellectual property portfolio.

Our lead Imotope™, IMCY-0098, is in phase 2 clinical testing for early onset type 1 diabetes.


Biotechnology

Life Sciences

Therapeutics

Imcyse SA

Denis Bedoret

Jean van Rampelbergh

Antoon van Oosterhout

Hugues Wallemacq

Andrew Mackie

The Leadership Team at Imcyse SA is responsible for steering the company towards achieving its vision of becoming a leader in the field of active specific immunotherapy. Comprising the Chief Executive Officer, VP of R&D - CSO, Chief Business Officer, and Chief Clinical Development Officer, the team oversees the strategic direction, clinical development, and business operations. This includes guiding research and development initiatives, managing clinical trials, fostering partnerships, and ensuring the company's innovative Imotope™ technology advances towards clinical success and market-ready solutions for autoimmune diseases.

Leadership Team

Management

Scientific Research and Development

Leadership Team

About

Team members

Other teams at Imcyse SA

Management

Scientific Research and Development